Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - Jama, 2013 - jamanetwork.com
Importance The prognosis for patients with pancreatic cancer is poor, even after resection
with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced …
被引用次数：1903 相关文章
[PDF] krupp-krankenhaus.de

[PDF][PDF] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - JAMA, 2013 - krupp-krankenhaus.de
OBJECTIVE To analyze whether previously reported improvement in disease-free survival
with adjuvant gemcitabine therapy translates into improved overall survival. DESIGN …

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer.

H Oettle, P Neuhaus, A Hochhaus… - JAMA: Journal of …, 2013 - search.ebscohost.com
IMPORTANCE The prognosis for patients with pancreatic cancer is poor, even after
resection with curative intent. Gemcitabine-based chemotherapy is standard treatment for …

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Importance The prognosis for patients with pancreatic cancer is poor, even after resection
with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced …
[PDF] lekarskenoviny.sk

[PDF][PDF] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - JAMA, 2013 - lekarskenoviny.sk
OBJECTIVE To analyze whether previously reported improvement in disease-free survival
with adjuvant gemcitabine therapy translates into improved overall survival. DESIGN …
[PDF] llusurgonc.org

[PDF][PDF] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - JAMA, 2013 - llusurgonc.org
OBJECTIVE To analyze whether previously reported improvement in disease-free survival
with adjuvant gemcitabine therapy translates into improved overall survival. DESIGN …
[HTML] unirioja.es

[HTML][HTML] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial

H Oettle, P Neuhaus, A Hochhaus… - JAMA: the journal of …, 2013 - dialnet.unirioja.es
Importance The prognosis for patients with pancreatic cancer is poor, even after resection
with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced …
[PDF] 91sqs.net

[PDF][PDF] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - JAMA, 2013 - sys.91sqs.net
OBJECTIVE To analyze whether previously reported improvement in disease-free survival
with adjuvant gemcitabine therapy translates into improved overall survival. DESIGN …

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

H Oettle, P Neuhaus, A Hochhaus, JT Hartmann… - JAMA, 2013 - europepmc.org
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with
resected pancreatic cancer: the CONKO-001 randomized trial. - Abstract - Europe PMC Sign in …

[引用][C] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial

H OETTLE, P NEUHAUS, M SINN… - JAMA, the journal of …, 2013 - pascal-francis.inist.fr
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With
Resected Pancreatic Cancer: The CONKO-001 Randomized Trial CNRS Inist Pascal-Francis …